Drs. Marc Potenza and Stephanie O'Malley are co-Directors of the Clinician Scientist Training Program
Dr. Potenza has significant expertise and experience in clinical research, leadership, administration and mentoring. Dr. Potenza’s focuses on clinical research of substance and non-substance (“behavioral”) addictions. His multifaceted, developmentally informed research program includes clinical trials, multimodal neuroimaging and genetic approaches and their integration. Major accomplishments include imaging and clinical trials studies that link pathological gambling with substance addictions, with such work in part leading to pathological gambling being considered for categorization with substance use disorders in DSM-5. He is currently PI on a Center of Excellence in gambling research that focuses on genetic and neural factors related to pathological gambling and its treatment and multiple PI on an R01 that focuses on understanding the neural correlates of the durability of cognitive behavioral therapy for cocaine addiction. Additionally, Dr. Potenza is co-Director of the Clinician Scientist Program, organizes and teaches in the core seminars, has chaired the CMHC Pharmacy and Therapeutics Committee for approximately 15 years, and serves as research mentor for multiple trainees. He has mentored over 60 early career investigators, including over 10 individuals with entry-level NIDA or NIAAA K Awards (including 2 current Scholars).
Dr. O’Malley’s research focuses on behavioral pharmacology, clinical trials of psychosocial and behavioral interventions with substance abusers, and studies of risk for alcoholism and nicotine dependence. Dr. O'Malley is co-Director of the Clinician Scientist Program, teaches in the core seminars, holds a Senior Scientist and Mentoring K05 and has mentored multiple past and current trainees and other junior faculty members including many women who are now internationally renowned addictions researchers. Dr. O’Malley has made seminal contributions to addiction treatment, including having conducted initial investigations of naltrexone, including one of the two pivotal studies used in the FDA approval of naltrexone for alcohol dependence and the development of a laboratory alcohol self-administration model that has been used by NIH, pharma and academic investigators to evaluate several compounds for alcoholism. She has made substantial contributions to tobacco research through her leadership of the Transdisciplinary Tobacco Use Research Center at Yale, funded by NIDA, NCI and NIAAA. She has an exceptional track record of leadership within the Department of Psychiatry as the Director of the Division of Substance Abuse Research (DSA), as the President of the Research Society on Alcoholism, and as a leader of multi-site clinical trials and transdisciplinary research.